Menthol Marco Viti 1% Cutaneous Powder 100g

NAME
MARCO VITI MENTHOL 1% SKIN POWDER

PHARMACOTHERAPEUTIC CATEGORY
Antipruritic, including antihistamines, anesthetics, etc.

ACTIVE PRINCIPLES
Menthol.

EXCIPIENTS
Talc.

INDICATIONS
The medicine is indicated in the symptomatic treatment of skin rashes due to exanthematous diseases, irritation, including from rubbing, itching and burning in case of insect bites, sunburn and burns.

CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity to the active substance (s) or to any of the listed excipients; children up to 30 months of age; children with a history of epilepsy or febrile seizures.

DOSAGE
Sprinkle the affected area evenly 2 or more times a day. The medicine is contraindicated in children up to 30 months of age. The duration of treatment should not exceed 3 days.

STORAGE
Keep the container tightly closed to protect the medicine from light.

WARNINGS
Pediatric population: the product should be used with caution in children up to 6 years of age. This product contains terpene derivatives which, in excessive doses, can cause neurological disorders such as convulsions in infants and children. The routine use in the daily hygiene of the child is not recommended as inhalation can cause lung irritation with the risk of severe breathing difficulties and death. If it is suspected that the child has inhaled the medicine, respiratory function should be carefully monitored as the onset of symptoms may be delayed for several hours. Hemolysis and kernicterus may occur in neonates with glucose 6-phosphate dehydrogenase deficiency exposed to menthol. The medicine is to be used for external use only; it must not be inhaled and must not be applied to eyes and mucous membranes. It should not be applied to open wounds or surgical gloves. The treatment should not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as camphor, cineole, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needles, eucalyptus and turpentine (due to their lipophilic properties the speed of metabolism and disposal is not known) in tissues and brain, in particular neuropsychological disorders. A higher dose than recommended should not be used to avoid an increased risk of adverse drug reactions and dose-related disturbances. Abuse of intranasally administered medicinal products containing talc as an excipient has been reported to cause pulmonary granulomas. Although talc does not cause acute toxicity, fatal cases have been reported following acute exposure to talc. Inhalation of the poor caused death, mainly in infants. Inhalation of talc causes irritation of the respiratory tract, coughing, wheezing, sneezing, vomiting, and cyanosis. The onset of these symptoms can occur in the following 12 - 24 hours. Acute exposure can cause permanent lung effects. Intense and prolonged exposure to talc can cause pneumoconiosis. When injected intravenously it can cause retinopathy, emboli and pulmonary hypertension. The application of talc on open wounds can cause severe granulomatous reactions. Talc is a highly irritating agent for the eyes and can cause symptoms, in some cases requiring surgical correction.

INTERACTIONS
The drug should not be used concomitantly with other products (medicinal or cosmetic) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).

SIDE EFFECTS
Pediatric population: due to the presence of menthol and in case of non-observance of the recommended doses, there may be a risk of convulsions in children and newborns. The following are the side effects of menthol, organized according to the MedDRA System Organ Class. Insufficient data are available to determine the frequency of the listed effects. Skin and subcutaneous tissue disorders: contact dermatitis. Cases of granulomas have been reported due to contamination of the umbilical cord residue with talcum powder. The reporting of suspected adverse reactions that occur after the authorization of the drug is important, as it allows continuous monitoring of the benefit / risk ratio of the drug.

PREGNANCY AND BREASTFEEDING
There are no or limited amount of data from the use of menthol in pregnant women. The drug is not recommended during pregnancy and in women of childbearing potential who do not use contraceptive measures. There is insufficient information on forgotten excretion in breast milk. The medicine should not be used during breastfeeding.